Valneva SE
PAR:VLA

Watchlist Manager
Valneva SE Logo
Valneva SE
PAR:VLA
Watchlist
Price: 1.895 EUR -1.51%
Market Cap: 307.9m EUR
Have any thoughts about
Valneva SE?
Write Note

Valneva SE
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Valneva SE
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Revenue
€24.9m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
OSE Immunotherapeutics SA
PAR:OSE
Revenue
€83.4m
CAGR 3-Years
83%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Valneva SE
Glance View

Market Cap
307.9m EUR
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VLA Intrinsic Value
6.044 EUR
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Valneva SE's Revenue?
Revenue
229.4m EUR

Based on the financial report for Sep 30, 2024, Valneva SE's Revenue amounts to 229.4m EUR.

What is Valneva SE's Revenue growth rate?
Revenue CAGR 1Y
-45%

Over the last year, the Revenue growth was -45%.

Back to Top